Altimmune announced FDA clearance of AdCOVID IND application
On Feb. 17, 2021, Altimmune announced that the U.S. Food and Drug Administration (FDA) had cleared the Companyls…
-
-
Labcorp added high sensitivity antigen test to screen for active COVID-19 infection
On Feb. 17, 2021, LabCorp announced the availability of a new laboratory-based antigen test that will help doctors…
-
Pfizer and BioNTech announced supply the European Union with 200 million additional doses of COMIRNATY
On Feb. 17, 2021, BioNTech announced an agreement with the European Commission (EC) to supply an additional 200…
-
Immunic announced 200 patients enrolled in phase 2 CALVID-1 trial of IMU-838 for treatment of COVID-19
On Feb. 17, 2021, Immunic announced that its lead asset, IMU-838, the company’s selective oral DHODH inhibitor, had…
-
Study published in NEJM demonstrated Pfizer-BioNTech COVID-19 vaccine neutralize South African variant spike mutations
On Feb. 17, 2021, BioNTech announced results from an in vitro study that provided additional data on the…
-
XPhyto announced completion of European CE-IVD application for 25-Minute COVID-19 RT-PCR test
On Feb. 16, 2021, XPhyto and 3a-diagnostics announced that all actions and procedures required for its European regulatory…
-
AIM ImmunoTech announced approval to commence phase 1 clinical study of Ampligen as intranasal COVID-19 therapy
On Feb. 16, 2021, AIM ImmunoTech announced that it had received approval from the required Ethics Committee in…
-
Moderna provided U.S. COVID-19 vaccine supply update
On Feb. 16, 2021, Moderna provided a supply update for their COVID-19 Vaccine in the United States, reporting…
-
Johnson & Johnson announced submission of Marketing Authorisation Application to EMA for Janssen COVID-19 vaccine candidate
On Feb. 16, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, has submitted a conditional Marketing Authorisation…
-
WHO listed 2 additional COVID-19 vaccines for emergency use and COVAX roll-out
On Feb. 15, 2021, the WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving…
-
Novavax announced expanded agreement with SK Bioscience for 40 million doses of COVID-19 vaccine for South Korea
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
-
Four potential COVID-19 therapeutics enter phase 2/3 testing in NIH ACTIV-2 trial
On Feb. 12, 2021, the NIH announced that enrollment had begun to test additional investigational drugs in the…
-
Canada purchased additional 4 million doses of Moderna’s COVID-19 vaccine
On Feb. 12, 2021, Moderna announced that the Canadian Government had increased its confirmed order commitment by 4…
-
Pfizer and BioNTech announced agreement to supply US with 100 million additional doses of COVID-19 vaccine
On Feb. 12, 2021, BioNTech announced that the U.S. government had exercised its option for an additional 100…
-
Rising mortality as Africa marked one year of COVID-19
On Feb. 11, 2021, the WHO announced that COVID-19 cases and deaths surged in Africa as more contagious…
-
ImmunityBio and NantKwest announced FDA authorization to study hAd5 T-cell COVID-19 vaccine
On Feb. 11, 2021, ImmunityBio and NantKwest announced they had received FDA authorization to expand Phase I testing…
-
Cue Health’s connected point-of-care Covid-19 test demonstrated 97.8% agreement compared to Central Lab PCR Testing
On Feb. 11, 2021, Cue Health announced the results of an independent clinical validation study conducted by Mayo…
-
Qatar Ministry of Public Health issued Emergency Use Authorization for COVID-19 Vaccine Moderna
On Feb. 11, 2021, Moderna announced that the Qatar Ministry of Public Health had issued an emergency use…
-
US Government purchased additional 100 million doses of Moderna’s COVID-19 Vaccine
On Feb. 11, 2021, Moderna announced that the U.S. government had purchased an additional 100 million doses of…
-
Relief confirmed release of preliminary findings from phase 2b/3 trial of intravenous RLF-100ﾙ (aviptadil)
On Feb. 10, 2021, RELIEF THERAPEUTICS announced the release of preliminary results from the phase 2b/3 trial of…
-
USDA confirmed COVID-19 in a cougar and tiger at a wild animal exhibitor in Texas
On Feb. 10, 2021, the United States Department of Agriculture (USDA) National Veterinary Services Laboratories announced confirmation of…
-
BioNTech updated vaccine production manufacturing site in Marburg, Germany
On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to…
-
FDA authorized Eli Lilly’s monoclonal antibodies for treatment of COVID-19
On Feb. 9, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab…
-
Moderna announced COVID-19 vaccine supply agreements with governments of Taiwan and Colombia
On Feb. 9, 2021, Moderna announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government…
-
US COVID-19 infections nearly three times greater than reported, UTSW model estimated
On Feb. 8, 2021, a machine-learning algorithm developed at UT Southwestern estimated that the number of COVID-19 cases…
-
Clinical trial in hospitalized COVID-19 patients evaluate long-acting antibody therapy
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
-
Eiger announced ILIAD study results of peginterferon lambda in COVID-19 published in Lancet
On Feb. 8, 2021, Eiger BioPharmaceuticals announced that the final results from the Phase 2 ILIAD (Interferon Lambda…
-
NanoViricides’s antiviral drug candidate for treatment of COVID-19 infections well tolerated in animal safety studies
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
-
Repligen and Navigo Proteins announced the launch of affinity resin for the purification of COVID-19 vaccines
On Feb. 8, 2021, Repligen and Navigo Proteins announced that they have completed the development and initiated the commercial…
-
Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
